Estrogen patches in short supply as demand for menopause hormone therapy grows [CNN]
Viatris Inc. (VTRS)
Company Research
Source: CNN
For a couple of anxious weeks in January, she had to go without them entirely. “There's definitely some symptoms that I noticed popping back after I went off of the patch for a while, and they still haven't completely gone away since then,” said Padgett, who is in perimenopause. After a long stretch of uncertainty, she is now finally able to access estrogen patches at a small independent pharmacy in her neighborhood. But each time she walks up to the counter to refill her prescription, she worries about hearing those three words she's come to fear: “Out of stock.” For many women in the United States who encounter drenching night sweats, sudden hot flashes, debilitating exhaustion and other menopause-related symptoms, small estradiol patches have become a steady source of relief. That relief is becoming harder to find – and doctors brace themselves for potentially more shortages to come. Manufacturers point to a rise in demand, driven by a greater awareness of menopause care
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia [Yahoo! Finance]Yahoo! Finance
- FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of PresbyopiaPR Newswire
- Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow [Yahoo! Finance]Yahoo! Finance
- Estrogen patches in short supply as demand for menopause hormone therapy grows [CNN]CNN
- UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade [Yahoo! Finance]Yahoo! Finance
VTRS
Earnings
- 11/6/25 - Beat
VTRS
Sec Filings
- 2/13/26 - Form 3
- 2/4/26 - Form SCHEDULE
- 2/3/26 - Form 8-K
- VTRS's page on the SEC website